Needham & Company analyst Mike Matson initiates coverage on BioTelemetry (NASDAQ: BEAT) with a Buy rating and a price target of $52.00.

For an analyst ratings summary and ratings history on BioTelemetry click here. For more ratings news on BioTelemetry click here.

Shares of BioTelemetry closed at $36.67 yesterday.